When?
Saturday, August 9, 2025
Where?
LAX Marriott
5855 W Century Blvd
Los Angeles, CA 90045
In partnership with University of Southern California (USC)
Agenda
9 AM - 9:30 AM | Registration
9:30 AM - 12 PM | Programming
Welcome Remarks and debra of America Updates | Brett Kopelan, debra of America Executive Director
Readthrough Therapy for Epidermolysis Bullosa | Mei Chen, PhD
AGLE-102 - Clinical Advancements in Regenerative Healing for DEB Patients | Shelley Hartman, CEO, Aegle Therapeutics
Mesenchymal Stem Cell-Derived Extracellular Vesicles for Epidermolysis Bullosa | Kathleen Miao
ZEVASKYN: A New FDA-Approved Gene Therapy for RDEB Wounds | Madhav Vasanthavada, PhD, MBA, Chief Commercial Officer, Head of Business Development, Abeona Therapeutics; featuring EB Community Member Noelle
Understanding FILSUVEZ and Its Role in Epidermolysis Bullosa (EB) | Leland Turner, PharmD, Medical Science Liaison & Athena Saunders-Hechavarria, Patient Education Liaison, Chiesi USA; featuring EB Community Member Henry
12 PM - 1 PM | Catered Lunch
1 PM – 3 PM | Programming
Experience with VYJUVEK | Bonnie Fainman, Patient Access Liaison, Krystal Biotech; featuring EB Community Member Vanessa
VYJUVEK at Home with Option Care Health | Jennifer Johnston, RN, BSN, Director, Product Management, Option Care Health
ABCB5+ Stem Cells for the Systemic Treatment of EB – An Update on the Phase III Trial | Dr. Christoph Ganss, CEO and Founder, RHEACELL
Your Cells, Our Science: Gene Therapy for Dystrophic Epidermolysis Bullosa | David Chu, MD, PhD, FAAD, Chief Medical Officer, Castle Creek Biosciences
3 PM – 4 PM | Social Hour
Featured Speaker:
Mei Chen, PhD
Professor of Dermatology
Keck School of Medicine of USC
